Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivimed Labs reported standalone revenue of ₹179.43 million for Q1 FY26, down ~27% from ₹246.36 million in Q1 FY25, and a net loss of ₹54.95 million (improved from a ₹151.11 million loss a year ago). The company disclosed it has defaulted on bank and financial institution dues of ₹3,748.22 million (₹374.8 crore), with all loan accounts classified as Non-Performing Assets (NPA) by banks. The auditor (SVRL & Co.) issued a qualified conclusion, flagging that the company has not booked interest expense of ₹149.83 million on its NPA loans while negotiating settlements, which understates losses. On a consolidated basis, net worth is already negative at ₹(406.62) million, and would worsen to ₹(556.45) million if the disputed interest were provided. The board also approved re-appointment of the Managing Director and two Executive Directors for 5 years and authorized pledging overseas subsidiaries' securities to raise loans or repay debt.
This is a deeply negative filing for shareholders: the company is effectively in financial distress with all bank loans in default and NPA status, recurring audit qualifications, negative consolidated net worth, and an active going-concern risk from ongoing settlement talks with lenders. The stock is likely to remain under pressure, and shareholders face significant dilution or restructuring risk if debt settlement terms are unfavorable.